MeritValue

MANGOCEUTICALS, INC.

MGRXdata completeness 75%4 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'incomeTaxExpense'

The thesis, from the filings

MANGOCEUTICALS, INC. earns about -6847% on invested capital, and has bought back 7% of its shares over 4 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2022FY 2023FY 2024FY 2025
Revenue$8,9391$731,4932$615,8733$456,0213
Net income−$2M4−$9.21M5−$8.71M6−$20.6M6
Operating cash flow−$1.35M7−$7M8−$4.86M9−$5.85M9
Capital expenditure$43,10210$3,51911——
Free cash flow (derived)−$1.39M7−$7M8——
Total debt————
Cash & equivalents$682,86012$739,00613$58,65314$1.49M14
Diluted shares10.8M1.1M2.0M10.1M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$15.09
your share of equity
Profit it earned you last year
−$20.5
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $15.09 of net worth that earned you −$20.5 last year.

iii. Is this a good business?
Moat signal · return on invested capital
-6847% avg · 4y
FY22 —FY23 -20373%FY24 -50%FY25 -119%

It earned an average -6847% on invested capital over 4 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−7% shares · 4y

Share count is down 7% over 4 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2022-12-31 · accession 0001493152-24-012508 (Revenues)
  2. 10-K · period ending 2023-12-31 · accession 0001641172-25-000085 (Revenues)
  3. 10-K · period ending 2024-12-31 · accession 0001493152-26-014478 (Revenues)
  4. 10-K · period ending 2022-12-31 · accession 0001493152-24-012508 (NetIncomeLoss)
  5. 10-K · period ending 2023-12-31 · accession 0001641172-25-000085 (NetIncomeLoss)
  6. 10-K · period ending 2024-12-31 · accession 0001493152-26-014478 (NetIncomeLoss)
  7. 10-K · period ending 2022-12-31 · accession 0001493152-24-012508 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2023-12-31 · accession 0001641172-25-000085 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2024-12-31 · accession 0001493152-26-014478 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001493152-24-012508 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K · period ending 2023-12-31 · accession 0001641172-25-000085 (PaymentsToAcquirePropertyPlantAndEquipment)
  12. 10-K · period ending 2022-12-31 · accession 0001493152-24-012508 (CashAndCashEquivalentsAtCarryingValue)
  13. 10-K · period ending 2023-12-31 · accession 0001641172-25-000085 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2024-12-31 · accession 0001493152-26-014478 (CashAndCashEquivalentsAtCarryingValue)